DuPont to cut work force, close plants

2 April 2001

DuPont has announced plans to cut 4,000 jobs, or about 4% of its globalwork force, as well as reduce contract personnel by 1,200. It is also planning to close "less competitive manufacturing assets," with half of the job cuts coming from DuPont's nylon and polyester fiber businesses. The firm said it will take a one-time charge in the second quarter of $0.40-$0.45 per share as a result of the action. The expected annual pretax payroll savings will be about $400 million.

Chief executive Charles Holliday said the company has taken these measures "to more rapidly achieve our goal of sustainable growth." This goal would no longer appear to involve health care, as the firm is willing to divest DuPont Pharmaceuticals, and a number of drugmakers, notably Novartis and Bayer, have expressed an interest in the business (Marketletters March 26 and April 2).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight